Transcode Therapeutics, Inc.
No SEC Form 4 filings for $RNAZ in the last 30 days.
See all $RNAZ insider activity →TransCode Therapeutics (RNAZ) presented Phase 1a trial data for TTX-MC138 at ESMO Congress 2026. The study met safety endpoints, showed dose-dependent exposure, and indicated disease stabilization and extended progression-free intervals in some patients. TTX-MC138 is being evaluated in a Phase 2a trial under the PRE-I-SPY program.
TransCode Therapeutics (RNAZ) will present Phase 1a clinical trial data for TTX-MC138, its lead therapeutic candidate, at ESMO Congress 2026. The poster highlights the evaluation of TTX-MC138 in patients with advanced solid tumors, targeting miR-10b, a microRNA linked to metastatic disease progression. The presentation is scheduled for October 23, 2026, in Madrid, Spain.
Transcode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement As previously disclosed by TransCode Therapeutics, Inc. (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2026, the Company entered into a Standby Equity P
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning RNAZ (Transcode Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent RNAZ coverage spans financial news, corporate actions and technology.
Positive safety data may lift the stock as investors anticipate further development.
The announcement may generate modest buying interest as investors anticipate data, but no concrete results are provided yet.
The financing waiver and prepayment improve liquidity and may support the share price.
Positive Phase 1a results likely lift sentiment and attract speculative buying.
The patent approvals strengthen the company's IP portfolio but have limited immediate financial impact.
AlphAI scores every news story that mentions RNAZ with an AI model for sentiment and relevance, and aggregates insider trades from Transcode Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TransCode Therapeutics (RNAZ) presented Phase 1a trial data for TTX-MC138 at ESMO Congress 2026. The study met safety endpoints, showed dose-dependent exposure, and indicated disease stabilization and extended progression-free intervals in some patients. TTX-MC138 is being evaluated in a Phase 2a trial under the PRE-I-SPY program.
2 min readTransCode Therapeutics (RNAZ) will present Phase 1a clinical trial data for TTX-MC138, its lead therapeutic candidate, at ESMO Congress 2026. The poster highlights the evaluation of TTX-MC138 in patients with advanced solid tumors, targeting miR-10b, a microRNA linked to metastatic disease progression. The presentation is scheduled for October 23, 2026, in Madrid, Spain.
1 min readTranscode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement As previously disclosed by TransCode Therapeutics, Inc. (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2026, the Company entered into a Standby Equity P
1 min readTranscode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors · I
2 min readTransCode Therapeutics (RNAZ) announced patent advancements in Australia and Japan for its RNA-based cancer therapy platform. The Australian patent covers siRNA delivery for cancer treatment, while the Japanese patent focuses on RNA-based immunomodulation. These developments strengthen the company's global IP portfolio and support its lead therapeutic candidate, TTX-MC138.
1 min readTranscode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director On September 1
1 min readSeveral biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
1 min readTenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.
6 min readRedChip Companies says it will air interviews on Bloomberg TV and CNBC featuring Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ). Virax CEO James Foster discusses post-fiscal 2026 balance sheet and Nasdaq bid compliance, plus ImmuneSelect supply talks. Transcode CEO Philippe Calais covers TTX-MC138 Phase 2a progress in ctDNA+ colorectal cancer.
2 min readTranscode Therapeutics, Inc. (RNAZ) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001829635 0001829635 2026-07-20 2026-07-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min read
